RT Journal Article
SR Electronic
T1 Initial Clinical Outcomes from NOCD Digital Behavioral Health Treatment of Obsessive-Compulsive Disorder Using Exposure and Response Prevention
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.18.20173633
DO 10.1101/2021.01.18.20173633
A1 Jamie D. Feusner
A1 Patrick B. McGrath
A1 Ted Faneuff
A1 Stephanie Lonsway
A1 Reza Mohideen
A1 Larry Trusky
A1 Stephen M. Smith
YR 2021
UL http://medrxiv.org/content/early/2021/01/20/2021.01.18.20173633.abstract
AB Effective first-line treatments for obsessive-compulsive disorder (OCD) include exposure and response prevention (ERP) therapy. Despite extensive evidence of its efficacy in clinical studies and real-world samples, ERP is still underutilized as a treatment, likely due to access to care barriers such as the availability of adequately trained ERP therapists, geographical location, time, and cost. NOCD has created a digital behavioral health treatment for OCD using ERP delivered via teletherapy and between-session support. We examined preliminary treatment outcomes in a large naturalistic sample of 2069 adults, children, and adolescents with a primary OCD diagnosis. Treatment consisted of twice-weekly live teletherapy ERP for three weeks, followed by six weeks of once-weekly brief teletherapy check-ins. Assessments were conducted at baseline, after completion of three weeks of twice-weekly sessions, and at the end of the six weeks of brief check-ins. Treatment resulted in significant improvements, with a 45% mean reduction in OCD symptoms and a 71% response rate (≥35% reduction in OCD symptoms).Treatment also resulted in a significant, 43% reduction in depression, a 49% reduction in anxiety, and a 35% reduction in stress symptoms. Quality of life improved by a mean of 35%. The mean duration of treatment was approximately 11 weeks, and the total therapist time was approximately 11 hours, which is less than half the total time compared with standard once-weekly outpatient treatment. In sum, in this preliminary sample, NOCD’s treatment model for OCD, delivered in a readily-accessible format for patients, has demonstrated to be effective and efficient.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: all authors had financial support from NOCD Inc for the submitted work Clinical TrialNCT04701372Funding Statementno external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UCLA IRB has determined the research to be exempt from IRB review and has stated the following: Based on the information that was provided in this application, this project does not meet the definition of Human Subject Research. Thus it is not necessary to submit the application to the IRB for review and approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be available upon request.